EMA committee issues positive opinion for Tesaro’s Zejula

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for Tesaro’s marketing authorization application for Zejula (niraparib) as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete response or partial response to platinum-based chemotherapy. This opinion will now be referred to the European Commission, which grants marketing authorization for medicines in the European Union. Pending the decision by the EC, Zejula would be the first oral, once-daily poly (ADP-ribose) polymerase 1/2 inhibitor approved in Europe for use in patients regardless of BRCA mutation or biomarker status.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology. 
Silverstein during his surgical oncology fellowship, c. 1972This month on the Cancer History Project Podcast, Melvin J. Silverstein, Medical Director of Hoag Breast Center and the Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery at USC, sat down with Stacy Wentworth, radiation oncologist and medical historian, to reflect on his career—and founding the first free-standing breast center.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login